Intellia Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Intellia Therapeutics Inc NTLA.OQ reported a quarterly adjusted loss of $1.10​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.12. The mean expectation of twenty two analysts for the quarter was for a loss of $1.28 per share. Wall Street expected results to range from $-1.49 to -89 cents per share.

• Revenue fell 42.5% to $16.63 million from a year ago; analysts expected $11.87 million.

• Intellia Therapeutics Inc's reported EPS for the quarter was a loss of $1.10​.

• The company reported a quarterly loss of $114.33 million.

• Intellia Therapeutics Inc shares had risen by 2.5% this quarter and lost 37.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 5.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Intellia Therapeutics Inc is $41.00

This summary was machine generated from LSEG data May 8 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)